Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MedBiome
Ottawa, Ontario, Canadamedbiome.ca ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MedBiome has developed the RapidAIM platform to screen compounds against individual microbiomes in vitro. They tested 43 compounds (including 4 antibiotics) against 5 individual microbiomes. They also reported the effects of berberine (BBR) and 16 structural analogs on seven individual gut microbiomes using their RapidAIM technology
- Therapeutic areas
- GastroenterologyOncologyNeurologyNephrology
- Modalities
- Microbiome therapeuticsMicrobiome nutritional compounds
- Industry
- Biotech
02
Partnerships
University of Ottawa
Beyond the preview
Go deeper on MedBiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedBiome.